Prevention of heart failure has been a major public health focus, founded on knowledge of pathogenic mechanisms and modifiable risk factors for hypertension and coronary artery disease (1) . Heart failure remains an idiopathic condition, however, in 50% of adults (2) and 66% of children (3) referred to cardiologists, and end-stage idiopathic dilated cardiomyopathy (DCM) is the most common indication for cardiac transplantation (4, 5) . Indeed, onset of heart failure symptoms in DCM typically portends advanced myocardial disease and risk for sudden death (6) after years to decades of clinically silent but insidiously progressive myopathy. Even in children, this inherent delay in diagnosis and treatment of DCM accounts for 10-year transplantation-free survival of only 42% (3) . Improved prediction, treatment, and prevention of DCM will require discovery of pre-clinical biomarkers, better tools for riskstratification, and the molecular and cellular basis of disease to enable mechanism-based therapies (1) .
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Recognition of DCM as a familial disorder in 20% to 48% of cases (7) (8) (9) (10) (11) has provided a rationale for routine screening echocardiography in at-risk relatives to detect pre-symptomatic disease (12) . Moreover, it has been the impetus for human genetics investigations to uncover the molecular basis of DCM (13, 14) . Since 1993, pathogenic mutations in over 20 genes encoding cytoskeletal, contractile, nuclear membrane, calcium-regulating, and ion channel proteins have been identified in patients with DCM (15) . The majority of studies are hypothesis-based, targeting candidate genes like cardiac actin (16) that encode proteins with established function in the heart. By contrast, unanticipated DCM genes and insights into disease pathobiology have emerged from rare families suitable for whole genome mapping studies (17) (18) (19) (20) . Here, we used genetic linkage analysis in 2 large families with autosomal-dominant DCM to map a disease locus, leading to discovery of a mutation hotspot within a ribonucleic acid (RNA)-binding protein gene associated with high morbidity and mortality.
Methods
Study subjects. Patients with DCM evaluated at the Mayo Clinic in the years 1987 to 1992 and 1999 to 2008 and their relatives were recruited, and medical records were reviewed. We enrolled 280 unrelated probands; familial DCM was confirmed in 24% (DCM documented in Ն1 first degree relative) and suspected in 27% (on the basis of history alone). Family history of sudden death was present in 18%. The 8 families described in the current study were white and of northern European ancestry by self-reporting. An ethnically matched group of 480 control subjects with normal echocardiograms was randomly selected from a communitybased cohort (21) . Subjects provided written informed consent under research protocols approved by the Mayo Clinic Institutional Review Board.
Echocardiograms in relatives were performed for clinical indications or under the auspices of the research study. Diagnostic criteria for DCM were: lack of an identifiable cause for disease, left ventricular diastolic and/or systolic dimensions Ͼ95th percentile indexed for body surface area (22) , and left ventricular ejection fraction Ͻ50%. Subjects with normal echocardiograms were classified as "unaffected," and those with equivocal or insufficient data were classified as "uncertain." Genomic deoxyribonucleic acid (DNA) was isolated from peripheral-blood white cells (Puregene Blood Kit, Gentra/QIAGEN, Valencia, California) or from paraffin-embedded tissue (QIAamp DNA FFPE Tissue Kit, QIAGEN). Linkage analysis and fine mapping. Genome-wide linkage analysis was performed with the ABI PRISM Linkage Mapping Set MD10, version 2.5 (Applied Biosystems, Foster City, California), consisting of polymerase chain reaction (PCR) primer pairs for 400 short tandem repeat markers. After PCR amplification of DNA samples, fragments were resolved on an ABI PRISM 3130xl, and genotypes were scored with GeneMapper Software (Applied Biosystems). Two-point and multipoint linkage analyses were performed using the FASTLINK program and specification of the following variables: a phenocopy rate of 0.001, equal marker allele frequencies, and dichotomous liability classes ("affected" and "unaffected"). For mutations, a frequency of 0.001 was specified. Logarithm of the odds (LOD) scores were determined for affected subjects only and for 80% and 100% penetrance models at recombination frequencies of 0.0 to 0.4.
Fine locus mapping was performed with microsatellite markers on physical maps, accessible on the website of the National Center for Biotechnology Information (NCBI) (23) . Genotyping was accomplished by PCR amplification of DNA radiolabeled with [alpha 32 P] deoxycytidine triphosphate, resolution of alleles by polyacrylamide-gel electrophoresis, and visualization by autoradiography. Scored genotypes were assembled as haplotypes to define the critical region. Mutation detection and haplotype analysis. Expression profiles of candidate genes, derived from Affymetrix GeneChip array data for 12 normal human tissues (accession GDS424) or 61 normal mouse tissues (accession GDS592), were assessed by searching the Gene Expression Omnibus (GEO) link on the NCBI website (24) . The genomic structure of RBM20 was based on predicted reference messenger ribonucleic acid (mRNA) sequence (accession NM_001134363.1), retrieved from NCBI. Primer pairs were designed for genomic DNA PCR-amplification of the coding regions of the 14 predicted exons (Online Table 1 ), with Oligo Primer Analysis Software, version 6.71 (Molecular Biology Insights, Cascade, Colorado). For sequencing, amplified products were treated with ExoSAP-IT (USB Corp., Cleveland, Ohio) and sequenced by the dye-terminator method with use of an ABI PRISM 3730xl DNA Analyzer (Applied Biosystems). The DNA sequences were viewed and analyzed with Sequencher, version 4.5 DNA analysis software (Gene Codes Corp., Ann Arbor, Michigan). The reference mRNA and derived protein sequence (accession NP_001127835.1) were used for annotation of identified mutations.
Denaturing high-performance liquid chromatography (DHPLC) heteroduplex analysis (WAVE DHPLC System, Transgenomic, Omaha, Nebraska) was used to screen for sequence variants in our DCM cohort and control samples. Ideal buffer gradients and column melting temperatures were determined with Transgenomic Navigator software version 1.7.0 Build 25 and subsequent optimization (Online Table 1 ). Chromatographic elution profiles of amplified fragments were compared against the wild-type homoduplex pattern; samples yielding anomalous traces were selected for sequencing. To test for a common founder among families with the same RBM20 mutation, haplotypes for mutant alleles were constructed from an intragenic tetranucleotide-repeat sequence and single nucleotide polymorphisms, identified by sequencing family members. Cardiac mRNA expression and protein structure analysis. Total RNA was extracted from frozen human heart tissue (RNeasy Fibrous Tissue Midi Kit, QIAGEN), and 1.0 g was reverse transcribed with an oligo(dT) primer to produce complementary deoxyribonucleic acid (cDNA) from mRNA (SMART RACE cDNA Amplification Kit, Clontech, Mountain View, California). Primers cDNA-F (CCTACCCCAGATCATCCAAAATGC) and cDNA-R (AACAAACACTTTGCAGTCAGTTATACA) were designed to PCR amplify and sequence 5=-RACE-Ready cDNA, spanning the RBM20 region containing the identified mutations. A subsequent nested reaction with primers cDNA-2F (GAACCCATTCTCGGTCAGTAACCC) and cDNA-2F/3=UTR-R (TCTCTCTGCCCTTCCTC-CATTAGT) was performed to provide optimal sequence quality. The RBM20 reference protein sequence was subjected to a Conserved Domain Database search performed with BLASTP, accessed on the NCBI website, to identify conserved structural domains. Conservation of amino acids altered by RBM20 missense mutations was investigated by aligning our translated RBM20 cDNA sequence with RBM20 protein sequences of other species.
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Results
Phenotype of index families. Clinical data and DNA samples were collected from 2 large families in which a clinically aggressive form of DCM segregated as an autosomal-dominant trait ( Fig. 1 1A ), a region spanning 19.3 Mb, which was inherited by all affected subjects (peak multipoint LOD score 3.62 for all subjects, assuming 100% mutation penetrance, and 2.67 for affected subjects only). A recombination event within this interval occurred in a 43-year-old woman with a normal echocardiogram (III.14). The critical region narrowed to 4.6 Mb, assuming she did not inherit the disease-associated mutation. Fine mapping in DC-35 identified an overlapping disease-associated haplotype (Fig. 1B ) spanning 22.8 Mb (peak multipoint LOD score 4.89 for all subjects, assuming 100% mutation penetrance, and 3.58 for affected subjects only). The haplotypes were different for each family, suggesting they did not share common ancestry, yet the overlapping disease loci raised the possibility of a shared DCM gene. Mutation identification. Candidate genes were selected from the 19.3-Mb critical region in DC-12, comprising more than 150 genes, on the basis of cardiac expression and/or physiologic rationale. Mutations within exons of 25 genes were excluded by DNA sequencing (Online Table 2 ). RBM20, a gene with unknown function, was included on Continued on next page the basis of its genomic location and expression pattern. Among 12 human tissues, RBM20 is most highly expressed in the heart, with transcript abundance 4-fold greater in cardiac than in skeletal muscle according to GEO array data. Moreover, it is 1 of only 19 genes with a mean expression in the heart Ͼ8-fold higher than the combined mean expression in 11 other tissues. Similarly, among 61 murine tissues it is most highly expressed in heart (Ͼ5-fold skeletal muscle). Sequencing of the 14 exons of RBM20 identified a distinct heterozygous missense mutation in exon 9 in each family, resulting in a P638L substitution in DC-12 and a R634Q substitution in DC-35 ( Figs. 1 and  3A ). Mutations cosegregated with the disease phenotype and were absent in unaffected family members and 480 ethnically matched control subjects.
To determine whether RBM20 mutations were present in other cases of DCM, we screened the 14 coding exons in our remaining cohort of 278 subjects with DHPLC. Three unique heterozygous missense mutations-R636S, R636H, and S637G-were identified in 6 other families, all clustered within exon 9 (Figs. 2 and 3A) . Among the 8 families with RBM20 mutations, 2 had an identical mutation resulting in P638L substitution, and 3 had an identical mutation resulting in R636S substitution. Haplotype analysis (Online Table 3 ) excluded a common ancestral founder for the P638L substitution. Although the disease-associated haplotypes were the same in the 3 families with an R636S substitution, the majority of individual alleles comprising the haplotype are the most common variants within a white European population. Consequently, a founder effect could not be conclusively established. Mutations were absent in control samples and cosegregated with DCM in the 7 families where DNA samples were available from 2 or more affected subjects. Combined peak 2-point LOD scores for mutations versus DCM in the 4 largest families (DC-12, DC-35, DC-27, DC-50) ranged from 8.02 (affected subjects only) to 11.49 (all subjects, assuming 100% mutation penetrance). Cardiac mRNA expression and protein structure analysis. RBM20 comprises, on the basis of the predicted reference cDNA (mRNA), 14 exons (Fig. 3B) . Portions of exons 2 and 14 and all of exons 3 through 13 were verified in a single open reading frame cDNA derived from oligo(dT)-primed heart RNA (Fig. 3B) . This confirmed that these exons are transcribed and spliced into mRNA in the heart, including exon 9, which contained the cluster of identified RBM20 mutations. A Conserved Domain Database search of the translated reference RBM20 cDNA indicated homology to an RNA Recognition Motif 1 Superfamily domain spanning exons 6 and 7 (e-value ϭ 0.005) and a U1 zinc finger domain (e-value ϭ 2e Ϫ4 ) spanning exons 13 and 14. Additionally, exon 9 encodes an arginine/serine (RS)-rich domain, which is disrupted by the 5 identified unique missense mutations. Each resultant amino acid substitution alters a residue in RBM20 conserved among diverse species (Fig. 3C) . 
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Mutations in RBM20 Cause Familial DCM Genotype-phenotype correlation. RBM20 mutations were associated with clinically aggressive DCM. Collectively, the 39 subjects in our 8 families with a mutation and confirmed DCM were diagnosed 9 years earlier than a comparable series of patients with sporadic and familial DCM who underwent family screening (mean age at diagnosis 35.9 vs. 45.2 years) (7). Death occurred in 11 (mean age 45.2 years) and was deemed sudden in 3; 4 underwent cardiac transplantation (mean age 28.5 years); and 8 underwent ICD insertion. Subjects who enrolled in our study, however, did not fully represent the malignant nature of their familial disease as revealed by their pedigrees. Among the 32 additional relatives with suspected DCM by family history, for whom medical records were unavailable and/or mutation status could not be determined, 13 died suddenly (mean age 32.7 years), 3 underwent cardiac transplantation, and 3 had ICD insertion. There were no consistent electrocardiographic features in subjects with an RBM20 mutation; 9 had ventricular tachycardia. Variable degrees of myocyte hypertrophy and interstitial fibrosis were observed on histopathological analysis. Most enrolled subjects with accessible follow-up data had advanced disease and exhibited minimal improvement or further deterioration on medical treatment, although drug therapy was highly variable. Correlation between RBM20 mutations and phenotype was not without exception, however. There were 5 female subjects who inherited a mutation but did not fulfill diagnostic criteria for DCM: 1 subject in DC-35 (age 24 years) and 3 subjects in DC-27 (ages 15, 39, and 64 years) had left ventricular enlargement with normal ejection fraction; 1 subject in DC-9 (age 27 years) had a normal echocardiogram. No overt noncardiac phenotypes were evident among subjects with RBM20 mutations.
Discussion
Molecular basis of disease. The majority of known DCM genes encode cytoskeletal or contractile proteins of cardiac myocytes, with direct roles in the generation and/or transmission of contractile force through proteinprotein interactions (14) . An expanded understanding of the pathobiology of DCM has emerged from identification of mutations that perturb myocardial function via impaired calcium (25) , potassium (26), or sodium ion (18, 19) . Collectively, these molecular genetic etiologies for DCM reveal a fundamental defect in excitation-contraction coupling and the heart's capacity to perform under physiologic and stress conditions. Notable exceptions to this paradigm have been revealed through discovery of unsuspected DCM genes, like LMNA and EYA4, in large families suitable for linkage analysis. LMNA encodes lamin A/C, a ubiquitously expressed nuclear membrane protein. By unknown mechanisms, mutations in LMNA cause DCM and conduction system disease (17) or a spectrum of noncardiac disorders. EYA4 encodes a transcriptional coactivator, which interacts with DNA-binding transcription factors. Mutations in EYA4 are predicted to alter cochlear and cardiac gene expression, causing a syndrome of DCM and sensorineural hearing loss (20) . RBM20, here identified as a gene for familial DCM, suggests perturbation of posttranscriptional pre-mRNA processing as a distinct molecular basis for the disorder.
RBM20 encodes RNA binding motif protein 20, with a prototypical RNA-recognition motif followed by an RS domain (27) . These structural features are characteristic of a family of RNA-binding SR proteins that assemble in the spliceosome, a large multiprotein complex that orchestrates constitutive and alternative splicing of premRNA (28) . Indeed, over 70% of human genes express The predicted genomic structure of RBM20, consisting of 14 exons, is depicted to scale. Exons that encode peptides homologous to highly conserved functional domains-ribonucleic acid (RNA) recognition motif 1 (RRM-1, in purple), arginine/serine-rich region (RS-rich, in blue), and U1 zinc finger (zf-U1, in green)-are indicated. Putative start (ATG) and stop (TGA) codons are located in exons 1 and 14, respectively. A polyadenylation signal (AATAAA) is located at the 3' end of exon 14. Directly below the RBM20 genomic structure, cDNA amplification and sequencing confirmed transcription of messenger RNA from exons 2 to 14 in human heart tissue, as depicted by parallel alignment. The cDNA transcript contains the complete RS domain and identified RBM20 mutations in the 5' region of exon 9. (C) Alignment of homologous RBM20 protein sequences that flank the amino acid substitutions is shown. The RS domain spans residues 632 to 654, with arginine (R) and serine (S) residues highlighted in yellow. Residues conserved between human RBM20 and another species are indicated by (•) and amino acid deletions by (؊). Amino acids that are altered by the identified RBM20 missense mutations (residues 634, 636, 637, and 638, indicated with red bars) are conserved among all 8 species. Accession numbers: NP_001127835.1 for human, XP_508032 for chimpanzee, XP_544017 for dog, XP_603772 for cow, BAE24961 for mouse, NP_001101081 for rat, XP_421755 for chicken, XP_683222 for zebrafish, and CAG01297 for pufferfish.
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Mutations in RBM20 Cause Familial DCM multiple mRNA transcripts via alternative splicing of exons, conferring vast diversity to the proteome (29) . Heritable diseases are frequently attributable to cis-acting mutations, which disrupt normal splicing of the gene in which the mutation occurs. However, trans-acting mutations within spliceosome protein genes have been identified in only 3 human disorders-spinal muscular atrophy, retinitis pigmentosa, and Prader-Willi syndrome (28) . Such mutations have the potential to impair normal splicing of multiple genes, as recently demonstrated by exon microarray analysis in a mouse model of spinal muscular atrophy (30) . The specific function of RNA binding motif protein 20 in the human heart and the downstream effects of the identified RBM20 mutations that cause DCM remain unknown. However, a pathogenic link between genetic disruption of alternative splicing-regulating SR proteins of the spliceosome and DCM has now been established in mouse models (31) . Clinical implications. Since the first DCM-associated gene was identified by linkage analysis over 15 years ago (32, 33) , clinical application of research findings has proved challenging due to the marked genetic heterogeneity of DCM. Although routine genetic testing might be practical in certain heritable cardiac disorders (34) , no single gene or mutation for DCM has emerged as common (15) . Targeted genetic testing might be practical, however, in clinically defined subgroups. For example, mutations in LMNA and SCN5A have been associated with a cardiac syndrome of DCM, impaired automaticity and conduction, and atrial fibrillation (17) (18) (19) . By use of genome-wide linkage analysis, the present study further expands the spectrum of DCM genes. Remarkably, the 5 unique RBM20 mutations identified in 8 families are clustered within a single exon that encodes an RS-rich domain. In our cohort, this mutation hotspot accounted for 3% (8 of 280) of all DCM cases, 5% (8 of 151) of confirmed or suspected familial cases, and 13% (7 of 54) of cases with a history of sudden death. Our study highlights the importance of family screening to detect pre-symptomatic DCM (7, 12) . Indeed, 68% (43 of 63) of the subjects in our 8 families were asymptomatic and first diagnosed with DCM on the basis of a screening echocardiogram. Despite the lack of symptoms, the RBM20 mutations we identified were highly penetrant, and only 5 of 44 individuals with a mutation did not fulfill diagnostic criteria for DCM. In fact, 4 of these 5 subjects had left ventricular dilation, a known precursor to overt DCM (7, 10) . However, penetrance of familial DCM is age dependent, and the majority of subjects who enrolled in our study were adults. Discovery of the genetic basis for DCM in these families now enables a pre-clinical diagnosis in at-risk children and young adults. Given the malignant nature of RBM20 mutations, this knowledge would justify closer clinical follow up, meticulous attention to coexistent modifiable risk factors, and earlier institution of therapies proven to alter the natural history of heart failure (35) and decrease the risk of sudden death (6) .
